Synthetic Biology grants in Denmark

Closed

Funds companies and researchers scaling up precision-fermentation microorganisms that turn captured CO2 into food nutrients.

Closed

Funds research turning hard-to-recycle waste streams like plastics, flue gases and desalination brine into fuels, chemicals and materials, with EU contributions up to EUR 4 million per project.

Open

Funds Danish companies preparing Horizon Europe and EDF proposals by supporting proposal development.

Open

Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.

Open

Funds global vaccine and biologic countermeasure developers to build responses for epidemic pathogens.

Between cycles

Funds developing and validating gene-editing tools in animal and other model systems used to study the human brain.

Between cycles

Funds high-impact collaborative Huntington disease teams tackling complex mechanisms and novel therapeutic strategies with advanced team science.

Pays $100,000, and up to $10 million if patentable, for solving the origin of genetic code.

Between cycles

Funds early-stage life science ventures with seed and Series A equity across therapeutics and medical device innovation.

Closed

Funds organizations conducting clinical trials of vaccine candidates against CEPI priority pathogens and viral families through CEPI's Innovations Call for Proposals.

Awards 15,000 Euro plus exhibition space and mentoring to the winning early-stage company at the ACHEMA Start-up Award 2027, for new ventures in chemistry, process engineering or biotechnology.

Closed

Supports biosecurity research, policy work, and prevention planning for pandemic preparedness.

Closed

Funds organizations designing and early-stage testing of new vaccine candidates against CEPI priority pathogens and Disease X viral families, with awards up to $1M over 18 months.

Closed

Funds organizations conducting preclinical vaccine development for CEPI priority pathogens and Disease X exemplars through CEPI's Innovations call.

Closed

Funds accredited research institutions developing treatments for congenital dystroglycanopathies with grants up to $50,000.

Closed

Funds accredited research institutions developing treatments and care improvements for congenital-onset laminopathies with grants up to $100,000.

Closed

Funds global teams developing drug, biologic, dietary, or microbiome-based interventions that target placental and gut inflammatory pathways to improve fetal growth outcomes in low-income countries.

Closed

Supports United Kingdom human organ engineering collaborations focused on translational tissue platforms.

Closed

Runs a 10-week, no-cost, non-dilutive accelerator for early-stage security, resiliency, and dual-use founders, from Pre-Seed through Series A+, culminating in enterprise pilots and investor-ready pitches.

Closed

Funds global teams researching novel approaches to overcome infection, inflammation, and microbiome-related barriers that reduce the effectiveness of food fortification programs.

Open

Funds existing ERC grant holders in testing the commercial or societal potential of already-funded research through a fixed EUR 150,000 top-up grant.

Pays existing ERC grant holders a EUR 150,000 lump sum to explore the commercial or social innovation potential of their ERC-funded research.

Open

Funds five €1M projects that help universities and research organisations turn academic inventions into licences, spin-offs and industry deals.

Open

Pays international research consortiums roughly €3-3.75 million to build cross-regional creative-industry and cultural-diplomacy partnerships between Europe and world regions such as Africa, Asia and Latin America.